GLP1R and Alzheimer disease: GLP-1 receptor agonists such as liraglutide, lixisenatide, and semaglutide are on the market, already licensed to treat T2DM and obesity in the EU and other countries, have neuroprotective and anti-inflammatory effects in animal models of AD and PD and re-sensitize insulin signaling [199].